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Abstract
The immense majority of patients with chronic headaches can be controlled with medi-
cal treatments. However, there is a subset of them with poor response, and it is for those 
patients that new therapeutic strategies are being designed. Neuromodulation has been 
used for chronic pain management in many areas for the past 50 years. The applica-
tion of these techniques to the treatment of the most refractory chronic headache disor-
ders has offered hope to these patients. There is a large variety of different techniques, 
each of them particularly suitable to specific types of chronic headaches. The surgically 
implanted devices are still in use in some particularly recalcitrant cases. Nevertheless, 
new percutaneous devices allow new treatment strategies. Percutaneous devices do not 
always show the same effectivity as surgically implanted stimulating devices, but they 
are user friendly and have no serious adverse effects. Thus, they are becoming the treat-
ment of choice once the pharmacological means are no longer effective. In case of failure, 
the surgical procedures would still be available as a last resort.
Keywords: chronic headache, chronic migraine, cluster headache, neuromodulation, 
neurostimulation
1. Introduction
Chronic headache is one of the most frequent pain syndromes, affecting 3% of the population. 
It can be rather disabling [1, 2], particularly for young people who are most affected by it. 
The International Classification of Headache subdivides headaches into 300 different entities 
[3], each of those with a different pathophysiology and involving different anatomical struc-
tures. Pain can originate from the central nervous system, the cranium or the cervical area [4]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Primary headaches like tension headache, migraine (CM) or trigeminal autonomic cephala-
gias (TACs) show the highest incidence. TACs are particularly incapacitating [5]. Most cases 
can be controlled with medication and physiotherapy. Abuse of medication is common with 
these patients, via the dose, the drugs or both [6]. When the pharmacological and conservative 
treatments fail, surgery may be considered. In the past, ablative surgical techniques have been 
applied. These techniques have been replaced by neuromodulation techniques. In them, the 
anatomical structures are not lesioned, but instead, the electric impulses block the nervous struc-
tures in a reversible fashion [7]. These techniques can be subdivided into two broad categories: 
noninvasive and invasive [1]. The noninvasive options include transcranial stimulation either 
electric [8–10] or magnetic [11–13] and transdermal stimulation of occipital [14, 15], supraorbital 
[9, 14–19] or vagus [20–23] nerves. Invasive procedures include stimulation of occipital [5, 17, 
24, 25–35], supraorbital [19, 31, 36], infraorbital [31] or greater auricular [37] nerves as well as 
sphenopalatine ganglion [38–44], cervical spinal cord [45–48] or hypothalamus [4, 25, 27, 49–52].
Noninvasive neuromodulation techniques are user friendly and have low costs and few and 
minor side effects [8–15, 19–23]. Unfortunately, their effectivity is lower than their invasive 
counterparts. Invasive neuromodulation is reserved for the most refractory cases, as they are 
associated with increased aggressiveness, more severe adverse events (AE) and higher costs [7].
All costs have to be taken into consideration. The full cost of neuromodulation would include 
the disability grants, as well as further possible treatments for AEs [33, 34, 53].
Taking the net expenditure into consideration, some have reported that the reductions in cost 
are evident at 5-year postimplantation [53]. In any case, invasive neuromodulation must only 
be used in the most refractory cases and only after all other medical and noninvasive treat-
ments have failed [46]. This is particularly important due to the high incidence of AEs and the 
possibility of new surgical procedures to solve them [29, 33]. A trial of temporary stimulation 
is required to evaluate the possible response of a definitive implant [45, 46, 54] to avoid wast-
ing time and resources.
These techniques present promising new treatment strategies. The available evidence will be 
analysed, describing the possible future trends.
2. Historical aspects of neuromodulation
Electricity to treat chronic headaches was first used in ancient Rome [55], but it was not until 
the 1950s that neuromodulation was used in the treatment of chronic pain disorders [55, 56]. 
Thalamic stimulation to treat chronic headaches was introduced in 1976 [57] and percutane-
ous peripheral nerve stimulation a year later [58]. At the beginning of the 1990s, hypothalamic 
deep brain stimulation (hDBS) was applied to the treatment of some chronic headache syn-
dromes and particularly in TACs [59]. The first report of occipital nerve stimulation (ONS) to 
treat occipital neuralgia was in 1999 [60]. In the year 2000, the hypothalamic stimulation was 
applied in the treatment of drug-resistant cluster headache (CH) [61]. The first two cases of 
supraorbital nerve stimulation (SONS) were reported in 2002 [62]. The first cases of hDBS in 
the treatment of CH were reported in 2003 [61]. In 2004, the ONS was applied in the treatment 
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of CM [63]. The first case reported with cervical spinal stimulation (SCS) in the treatment 
of CH was in 2008 [64]. The first report on stimulation of the sphenopalatine ganglion was 
presented at 2009 [38]. Ever since, there has been an explosion of reports on the effectiveness, 
indications and AEs of all these techniques. Simultaneously new devices that allow percuta-
neous stimulation have reached the market, allowing new solutions to old problems.
3. Indications for neuromodulation
The first step is to diagnose the patient and select an appropriate treatment by an experienced 
team that is familiarised with all available treatments. Neuromodulation techniques are indi-
cated in cases that have failed all other medical treatments available for this specific headache 
type. It is also recommended that patients receive a psychological assessment.
The next step is to attempt noninvasive neuromodulation techniques particularly useful in 
this type of chronic headache. Should all fail, a period of temporary trial stimulation is suit-
able [33]. Patients showing no response are not implanted and are redirected to other forms 
of treatment. This temporary stimulation also helps to predict the results to be expected if the 
definitive implant is attempted [32, 46].
4. Classification of the different techniques
4.1. Noninvasive procedures
4.1.1. Transcranial electric stimulation (TES)
This technique involves applying a low amperage continuous electric stimulation directly 
to the scalp [10]. In most cases, the electric stimulus spreads out of the area covered by the 
electrodes [10]. AEs have been moderate, such as skin burns due to inadequate electrode skin 
contact, fatigue or local prickling and burning sensation during the stimulation [8, 10]. Its 
effectivity and experience are limited [8, 10].
4.1.2. Transcranial magnetic stimulation (TMS)
A magnetic field is applied to the head, inducing depolarization and electrical activity of the 
underlying brain cortex [65, 66]. Most have applied it to the left frontal motor area [11, 67, 68], 
but some have done it to the occipital region, particularly in migraine patients [69]. In chronic 
headache related to mild posttraumatic head injury (MTHI-H), it has shown ≥50% improve-
ment in pain intensity and frequency in 58.3% of the patients [11]. In migraine, some have 
reported a reduction of 31.2% in pain frequency and 37.8% in attack duration [70] in two-third 
of the patients [66]. The acute variant, with or without aura, seems to have a better response 
than the chronic one [67–72]. There seems to be a cumulative effect, so that the longer this 
treatment modality is applied, the greater is the attack duration reduction [69]. In migraine 
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patients, a randomised study comparing transcranial magnetic stimulation versus placebo 
showed a 76.6% versus 27.1% pain improvement [75], but these data were not confirmed by 
others [68]. Another study in this same disease compared this treatment modality with botu-
linum toxin injection, finding that although both treatment modalities provide pain relief, 
the last one is more effective [76]. In atypical facial pain, trigeminal neuropathic pain and 
cluster headache, it has shown ≥30% pain reduction in 73% of the patients [77]. Interestingly, 
enough older age and longer treatment duration were associated with a better response, while 
the type of facial pain showed little influence [77]. It has been applied to pregnant migraine 
patients with no untoward side effects [69]. Complications are rare and include a case of 
induced trigeminal autonomic cephalalgia that ceased after stopping the transcranial mag-
netic stimulation [78]. Some patients have reported transient drowsiness [75]. A continuous 
application is required for the effects to be persistent [69].
4.1.3. Transcutaneous supraorbital-supratrochlear stimulation
This technique involves a special equipment that looks like a pair of glasses, which has to be 
worn on the forehead. It provides a 50% chronic headache pain reduction, including CM [14, 
16, 18]. When used for CM prevention, it reduces the number of attacks but not their intensity 
[16, 18]. In episodic CM, patients induced a 50% headache frequency reduction in 38.2% of the 
patients [18]. Although not very effective, the only side effects are local discomfort, redness or 
temporary skin irritation [16].
4.1.4. Transcutaneous vagus nerve stimulation (VNS)
The first reports entailed electrodes implanted surgically around the vagal nerve in the neck 
[79]. However, it never gained acceptance because the procedure was invasive and the results 
are limited. In 2013, a percutaneous VNS device was introduced, showing promising results 
in the treatment of chronic CM (CM) [20, 23]. Its best advantage is that it is applied directly to 
the neck by the patient him/herself [21, 23]. Its main drawback is its low effectiveness (22%) 
[22, 23, 80]. It is well tolerated with minor side effects like neck twitching, raspy voice or red-
ness at the application site [22, 23, 81].
In CH, it is helpful in the episodic but not in the chronic type [80, 81]. In the episodic type, it 
induces a positive response in 26.7% of the cases [80]. Some have used it in the acute treat-
ment of the chronic variant of this disease with a higher than 50% pain reduction in 40% of 
the patients [81]. In CM, it provides a 50% or more pain reduction in 22–56.3% of the patients, 
which is better in the episodic than in chronic variant [20, 22, 82]. It has been helpful in a single 
case of hemicrania continua (HC) unresponsive to indomethacin [83].
4.2. Invasive procedures
4.2.1. Sphenopalatine ganglion stimulation (SPGS)
The sphenopalatine ganglion has been a target in the treatment of chronic headaches for over 
a century. Initially, destructive lesions were applied [84], but since 2009, neuromodulation is 
also available [38]. It is effective in two thirds of episodic CH cases, preventing at least 50% of 
attacks, showing a decrease in intensity of at least 50% or both [38, 41–43, 73, 74].
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SPGS is both preventive and therapeutic in acute phases [85, 87]. About 30% of the patients 
can stop the medication [85, 87]. A transoral technique has been described with a remote 
powering system that avoids extension leads and the need to replace the batteries [86], where 
patients switch-on the stimulation with a handheld remote controller when the pain attack 
starts [85]. This markedly reduces the incidence of AEs [86]. Some patients use the stimula-
tion continuously to reduce the attack incidence [85]. Bilateral stimulation is more effective 
than unilateral [39], but it is not so effective in the chronic variant of this disease [85]. AEs are 
uncommon and mild, including sensory loss in the maxillary region (81%) [87], that may last 
over 1 year (2–28%), epistaxis (13%), facial numbness (25%), and local pain (4%) [86]. SPGS 
has also been used successfully in CM [44].
4.2.2. Occipital nerve stimulation (ONS)
ONS is the stimulation of the distal branches of C
2
 and C3 nerve roots (greater and lesser occip-
ital nerves). The electrodes (one at each side) can be inserted either through a 2 cm midline 
skin incision at C
1
 level and tunnelled subcutaneously through a bent Touhy needle inserted 
laterally from the mastoid area or alternatively from a lateral approach with a bilateral mas-
toid area skin incision and the electrodes inserted from a lateral to medial direction with the 
Touhy needle [14, 60, 88]. As ONS only covers 85% of the head leaving the forehead uncov-
ered, some have combined it with SONS [15, 89, 90]. Percutaneous ONS is recommended to 
foresee the results of a permanent implantation [91]. In any case, a temporary external stimu-
lation must be performed before definitive implantation [35]. Those with no positive response 
are referred to other treatment modalities.
ONS has been used in chronic CH [5, 24–26, 28, 29, 32–35, 40], CM [29, 32, 33], TACs [5], 
hypnic headache (happening regularly sleep) [92], SUNCT/SUNA [93, 94], and occipital neu-
ralgia [32]. In chronic CH, it reduces the attack incidence in over 50% in 70% of patients [5, 
24, 25, 28, 33, 40]. In CM, its average success rate is 65.4% in 67.9–80% of the cases [29, 95]. In 
SUNCT/SUNA, bilateral ONS induced a 69% pain improvement in 77% of the patients [93, 
94]. In idiopathic intracranial hypertension, it has been used to treat the associated headache 
and the residual headache once the intracranial hypertension is resolved, with higher than 
75% pain improvement [89], but it requires bilateral stimulation [89].
AEs plague 33–70% of the cases [24, 25, 29, 33, 96]. Among them are lead erosion [19, 89], local 
infection [29, 33], electrode emigration [96, 97], lead breakage [28, 30, 33], hardware-related 
discomfort [98], hardware/stimulation dysfunction [25], and early battery depletion related to 
high energy consumption [25, 33]. Some technical modifications have been devised to reduce 
the chance of lead migration [97] that in some series reaches 24% [99]. These include using 
silicone glue with silicone anchors [100], 2-point anchoring stimulator leads with a tension-
relief loop [26], narrow paddle electrodes [101] and to insert the impulse generator as close 
as possible to the leads (i.e., supraclavicular area) [96]. Unfortunately, solving the AE entails 
additional surgical procedures in 26–40.7% of the cases [25, 29].
Simultaneous ONS and SONS in CH provide more than 50% pain reduction in over 70% 
of patients [14]. This dual stimulation has also been successful in HM [15] and TACs [19]. 
Although the results are promising, the number of cases is too small to draw any statistically 
significant conclusions.
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4.2.3. Great auricular nerve stimulation (GANS)
Pain relief was reported using this technique in a single case of persistent MTHI-Ha 90% [37]. 
Further studies are needed.
4.2.4. Supraorbital nerve stimulation (SONS)
The first case was reported in 2009 in the treatment of CH [36]. In this disorder, SONS pro-
duced more than 50% pain reduction in 71% of the patients [19, 36, 90]. In a series of five 
patients with TACs, it improved the pain in all of them, but the series is too short to draw any 
conclusions [19]. It can be used alone or associated with ONS [14, 15, 19, 90].
4.2.5. Cervical spinal cord stimulation (SCS)
The electrode is introduced in the epidural space at the upper thoracic level and advanced 
to the cervical spinal cord until its distal tip is at the C
2
 level. One or two electrodes are 
inserted. The leads are connected to a subcutaneous impulse generator inserted at the infra-
clavicular area [46].
SCS has been used in CM [46, 47], SUNA [54], CH [45, 64], and MTBI-HA [48], reducing 
the headache frequency and/or intensity by ≥50% in 71% of the patients [45–47]. In CM, it 
improves the headache by >30% in 50% of the cases [46, 47, 102]. The AEs are frequent (71%) 
and usually require system explant and replacement in a second surgery [102]. Among these 
AEs are infections (13%) and lead rupture or migration (17%) [45–47, 89].
4.2.6. Hypothalamic deep brain stimulation (hDBS)
hDBS was introduced in 2000 to treat drug-resistant CH [61]. It is useful in many types of 
chronic headache disorders like HC, CH, SUNCT/SUNA, and in TACs [4, 50]. In chronic 
CH, it results in reduction of ≥50% of the attacks in 60% of the patients [5, 40, 50, 52]. The 
response rate in HC and SUNA is 82% [49]. In TACSs, the improvement rate is >50% in 69.9% 
of patients [50].
AEs include incision site pain, subcutaneous dislodgement of the impulse generator, tran-
sient gaze disturbance (oscillopsia, diplopia), autonomic disturbances, myosis, dizziness, 
wound infection, cervical dystonia, intracranial haemorrhage, and lead disconnection 
or rupture [40, 49, 52]. Many of these complications require system explant [49]. hDBS is 
reserved for those very few cases, in which everything else has failed as death has been 
reported [50].
The target was initially in the posterior hypothalamus [103, 104], but other areas have also 
been used like the mesencephalic grey substance, the red nucleus, the fasciculus retroflexus, 
the dorsal longitudinal fasciculus, the ansa lenticularis, the medial longitudinal fasciculus or 
the medial thalamus superficialis [104]. In the latest years, the ventral tegmental area is used 
to decrease the chance of haemorrhages [49, 52].
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5. Indications and results for specific chronic headache disorders
5.1. Cluster headache (CH)
CH consists of bouts of unilateral periorbital pain lasting between 15 minutes and 3 hours 
that follow an annual pattern [105]. It is considered as the most painful headache type, with 
0.12% prevalence. About 10% of the cases cannot be controlled with medical treatment [34]. 
CH has two variants: chronic and episodic [106]. In the episodic, headache periods alter-
nate with others of remission, and the attacks last between 7 days and 1 year with a pain 
free period lasting at least 1 month [105]. The chronic variant represents 10–15% of the cases 
[34, 86] and has free pain periods shorter than 1 month or attacks that are present nonstop 
through at least 1 year [105].
Percutaneous VNS has been used in the acute treatment of the chronic variant of CH with a 
higher than 50% pain reduction in 40% of the patients [33, 42, 81, 107]. Although not univer-
sally effective, it is minimally invasive and with very minor and reversible AEs.
Both ONS [25, 26, 34] and SPGS [40–43, 73] are the first options among the invasive tech-
niques [5, 86]. About 70% of patients respond to these treatments with 48% of excellent 
responders [25, 34]. ONS together with SONS has been applied with >50% pain reduction 
in 71% of the patients [90]. Cervical SCS has also been used with some success [102]. hDBS 
should be left as the very last resource as its complications are more severe and potentially 
life threatening [5, 52].
5.2. Hemicrania continua (HC)
It is a continuous and unilateral headache (it only affects one side of the head), associated 
autonomic symptoms and episodes of increased headache intensity [105]. Indomethacin is the 
drug of choice, but some patients do not tolerate it due to side effects like hypertension, gas-
trointestinal problems (particularly when combined with aspirin), vascular events, or bron-
chial spasms [83]. In a single case, it was found to respond to noninvasive percutaneous VNS 
[83]. Others tried repetitive sphenopalatine ganglion block [108]. The data are not statistically 
significant, and no definite conclusions can be drawn.
5.3. Chronic migraine (CM)
CM is described as having migraine headaches 15 or more days in every month [99]. Worldwide, 
it is the seventh cause of disability [109]. It affects 2–5% of the adult population [3, 105, 110].
The transcranial stimulation has contradictory results, so no recommendations can be 
offered [9]. The cervical percutaneous VNS shows promising but moderate results, better 
in the episodic than in chronic variant [20, 111]. Transcutaneous SONS reduces the num-
ber of attacks but not its intensity [18, 111]. Much more efficient is the ONS via implanted 
electrodes [5, 24, 29, 46], with a success rate of 65.4% in 67.9–80% of the cases [29, 95]. 
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Unfortunately, 70% of the patients suffer AEs, 40.7% of which require a new surgical proce-
dure [29]. Some have combined the ONS with the SONS with ≥50% pain reduction in >70% 
of the patients [14]. The SCS has also been applied with 30% pain reduction in 50% of the 
cases [46].
5.4. Hemiplegic migraine
It is a very severe migraine variant, refractory to most known therapies and that often evolves 
to a very debilitating state. It has been treated with combined SONS and ONS with a 92% 
average decrease in the number of attacks [15]. The number of cases is limited, so further 
studies are needed.
5.5. Trigeminal autonomic cephalalgias (TACs)
TAC is a group of headache disorders characterised by unilateral headache accompanied 
by cranial autonomic symptoms. Although SONS has been attempted [19], ONS is the first 
option [27], reserving the hDBS to the most recalcitrant cases [49, 50, 52].
5.6. Short-lasting unilateral Neuralgiform headache attacks with autonomic 
symptoms (SUNA) and short-lasting unilateral neuralgiform headache attacks with 
conjunctival injection and tearing (SUNCT)
These consist of primary headache attacks associated with cranial autonomic dysfunction. 
In refractory cases, bilateral ONS induced a 69% pain improvement in 77% of the patients 
[93, 94]. Deep brain ventral tegmental area stimulation achieved a 78% headache rate 
improvement in almost all patients but with frequent AEs that at times required to explant 
the system [49].
5.7. Mild traumatic head injury-related headache (MTHI-H)
MTHI-H represents about 4% of the chronic headaches [112]. Transcranial magnetic stimula-
tion has shown a 57% improvement in the intensity and frequency in this disorder [11–13]. 
SCS or GANS [37] stimulation has been used, stimulating the left prefrontal cortex [11]. In 
both cases, there was a 90% headache frequency reduction. Unfortunately, only two case 
reports exist, and no conclusions can be drawn.
6. Availability and usefulness of ambulatory techniques that can be 
practiced at home
All noninvasive procedures can be safely practiced at home. Their only drawback is low effec-
tiveness, but they induce no harm in those in whom no beneficial results are obtained. Further 
studies are necessary. The AEs are minor and completely reversible once the device is no 
longer used. The biggest problem may arise from the economical point of view, as health 
providers could choose not to pay for treatments that show moderate response.
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7. Conclusions
Although the immense majority of chronic headache disorders can be controlled with phar-
macological means, there is a subset of patients that are refractory to all of them. A thorough 
diagnosis of the specific headache subtype is essential to provide an effective treatment. For 
those few refractory patients to the current available drugs, there are other treatment possibil-
ities. We have now a wide array of noninvasive techniques that can be tried as a first attempt. 
In case of failure, surgically implanted stimulating systems can be of help. We should choose 
the more suitable option to the specific headache variant, keeping in mind the effectivity pos-
sible incidence of AEs of each treatment. hDBS should be considered the very last resource, as 
it is associated with some serious AEs and potentially to death.
Appendices and nomenclatures
AE Adverse event
CH Cluster headache
CM Chronic migraine
GANS Great auricular nerve stimulation
HC Hemicrania continua
hDBS Hypothalamic deep brain stimulation
HM Hemiplegic migraine
MTHI-H Mild traumatic head injury-related headache
ONS Occipital nerve stimulation
SCS Spinal cord stimulation
SONS Supraorbital nerve stimulation
SPGS Sphenopalatine ganglion stimulation
SUNA Short-lasting unilateral neuralgiform headache attacks with autonomic 
symptoms
SUNCT Short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing
TACs Trigeminal autonomic cephalagias
TMS Transcranial magnetic stimulation
tSNS Noninvasive transcutaneous supraorbital neurostimulation
VNS Vagus nerve stimulation
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
131
Author details
Vicente Vanaclocha-Vanaclocha1*, Nieves Sáiz-Sapena2, José María Ortiz-Criado3 and 
Leyre Vanaclocha4
*Address all correspondence to: vvanaclo@hotmail.com
1 Department of Neurosurgery, Hospital General Universitario Valencia, Spain
2 Hospital 9 de Octubre, Valencia, Spain
3 Anatomy, Universidad Católica San Vicente Mártir, Valencia, Spain
4 Medical School, University College London, London, United Kingdom
References
[1] Leone M, Cecchini AP. Central and peripheral neural targets for Neurostimulation of 
chronic headaches. Current Pain and Headache Reports. 2017 Mar;21(3):16
[2] Schuster NM, Rapoport AM. New strategies for the treatment and prevention of pri-
mary headache disorders. Nature Reviews. Neurology. 2016 Oct 27;12(11):635-650
[3] Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. 
Headache. 2011 Aug;51(Suppl 2):77-83
[4] Altinay M, Estemalik E, Malone DA. A comprehensive review of the use of deep brain 
stimulation (DBS) in treatment of psychiatric and headache disorders. Headache. 2015 
Feb;55(2):345-350
[5] Láinez MJ, Guillamón E. Cluster headache and other TACs: Pathophysiology and neuro-
stimulation options. Headache. 2017 Feb;57(2):327-335
[6] Hsu ES. Medication overuse in chronic pain. Current Pain and Headache Reports. 2017 
Jan;21(1):2
[7] Puledda F, Goadsby PJ. An update on non-pharmacological Neuromodulation for the 
acute and preventive treatment of migraine. Headache. 2017 Apr;57(4):685-691
[8] Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, 
Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann 
CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda 
PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, 
Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner 
HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W. Low intensity transcra-
nial electric stimulation: Safety, ethical, legal regulatory and application guidelines. 
Clinical Neurophysiology: Official Journal of the International Federation of Clinical 
Neurophysiology. 2017 Jun 19
Transcranial Magnetic Stimulation in Neuropsychiatry132
[9] Schoenen J, Roberta B, Magis D, Coppola G. Noninvasive neurostimulation methods 
for migraine therapy: The available evidence. Cephalalgia: An International Journal of 
Headache. 2016 Mar 29
[10] DaSilva AF, Truong DQ, DosSantos MF, Toback RL, Datta A, Bikson M. State-of-art neu-
roanatomical target analysis of high-definition and conventional tDCS montages used 
for migraine and pain control. Frontiers in Neuroanatomy. 2015;9:89
[11] Leung A, Metzger-Smith V, He Y, Cordero J, Ehlert B, Song D, Lin L, Shahrokh G, 
Tsai A, Vaninetti M, Rutledge T, Polston G, Sheu R, Lee R. Left dorsolateral prefron-
tal cortex rTMS in alleviating MTBI related headaches and depressive symptoms. 
Neuromodulation Journal of International Neuromodulation Society. 2017 May 30
[12] Leung A, Fallah A, Shukla S, Lin L, Tsia A, Song D, Polston G, Lee R. rTMS in alleviat-
ing mild TBI related headaches–a case series. Pain Physician. 2016 Feb;19(2):E347-E354
[13] Leung A, Shukla S, Fallah A, Song D, Lin L, Golshan S, Tsai A, Jak A, Polston G, Lee 
R. Repetitive Transcranial magnetic stimulation in managing mild traumatic brain 
injury-related headaches. Neuromodulation Journal of International Neuromodulation 
Society. 2016 Feb;19(2):133-141
[14] Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, 
Silberstein SD, Sharan AD. Long-term pain reduction does not imply improved func-
tional outcome in patients treated with combined supraorbital and occipital nerve stimu-
lation for chronic migraine. Neuromodulation Journal of International Neuromodulation 
Society. 2016 Jul;19(5):507-514
[15] Reed KL, Will KR, Conidi F, Bulger R. Concordant occipital and supraorbital neurostimu-
lation therapy for hemiplegic migraine; initial experience; a case series. Neuromodulation 
Journal of International Neuromodulation Society. 2015 Jun;18(4):297-303; discussion 
304
[16] Przeklasa-Muszyńska A, Skrzypiec K, Kocot-Kępska M, Dobrogowski J, Wiatr M, Mika 
J. Non-invasive transcutaneous supraorbital Neurostimulation (tSNS) using Cefaly(®) 
device in prevention of primary headaches. Neurologia i Neurochirurgia Polska. 2017 
Apr;51(2):127-134
[17] Robbins MS, Lipton RB. Transcutaneous and Percutaneous Neurostimulation for head-
ache disorders. Headache. 2017 Apr;57(Suppl 1):4-13
[18] Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital Nerve stimulation 
(t-SNS) with the Cefaly(®) device for migraine prevention: A review of the available 
data. Pain Theraphy. 2015 Oct 14
[19] Vaisman J, Lopez E, Muraoka NK. Supraorbital and supratrochlear stimulation for tri-
geminal autonomic cephalalgias. Current Pain and Headache Reports. 2014 Apr;18(4):409
[20] Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H. Cervical 
non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of epi-
sodic and chronic migraine and migraine-associated sleep disturbance: A prospective 
observational cohort study. The Journal of Headache and Pain. 2015;16:101
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
133
[21] Yuan H, Silberstein SD. Vagus nerve stimulation and headache. Headache. 2017 Apr; 
57(Suppl 1):29-33
[22] Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G. Non-invasive vagus 
nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-
label study. The Journal of Headache and Pain. 2015;16:61
[23] Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive 
vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia: An 
International Journal of Headache. 2014 Oct;34(12):986-993
[24] Mekhail NA, Estemalik E, Azer G, Davis K, Tepper SJ. Safety and efficacy of occipital 
nerves stimulation for the treatment of chronic migraines: Randomized, double-blind, 
controlled single-center experience. Pain Practice : the Official Journal of World Institute 
of Pain World Institute of Pain. 2017 Jun;17(5):669-677
[25] Fontaine D, Blond S, Lucas C, Regis J, Donnet A, Derrey S, Guegan-Massardier E, Jarraya 
B, Dang-Vu B, Bourdain F, Valade D, Roos C, Creach C, Chabardes S, Giraud P, Voirin 
J, Bloch J, Rocca A, Colnat-Coulbois S, Caire F, Roger C, Romettino S, Lanteri-Minet 
M. Occipital nerve stimulation improves the quality of life in medically-intractable 
chronic cluster headache: Results of an observational prospective study. Cephalalgia: 
An International Journal of Headache. 2016 Oct 3
[26] Pittelkow TP, Pagani-Estevez GL, Landry B, Pingree MJ, Eldrige JS. Occipital Neuro-
modulation: A surgical technique with reduced complications. Pain Physician. 2016 
Oct;19(7):E1005-E1012
[27] Lambru G, Giakoumakis E, Al-Kaisy A. Advanced technologies and novel neurostimula-
tion targets in trigeminal autonomic cephalalgias. Neurological sciences : Official Journal 
of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 
2015 May;36(Suppl 1):125-129
[28] Bermejo PE, Torres CV, Sola RG. Occipital nerve stimulation for refractory chronic 
migraine. Revista de Neurologia. 2015 Jun 1;60(11):509-516
[29] Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, Sharan AD, Narouze 
S, Mogilner AY, Trentman TL, Ordia J, Vaisman J, Goldstein J, Mekhail N. Safety and effi-
cacy of peripheral nerve stimulation of the occipital nerves for the management of chronic 
migraine: Long-term results from a randomized, multicenter, double-blinded, controlled 
study. Cephalalgia: An International Journal of Headache. 2015 Apr;35(4):344-358
[30] Freeman JA, Trentman TL. Clinical utility of implantable neurostimulation devices in the 
treatment of chronic migraine. Medical Devices (Auckland, N.Z.). 2013 Nov 20;6:195-201
[31] Verrills P, Rose R, Mitchell B, Vivian D, Barnard A. Peripheral nerve field stimulation 
for chronic headache: 60 cases and long-term follow-up. Neuromodulation Journal of 
International Neuromodulation Society. 2014 Jan;17(1):54-59
[32] Palmisani S, Al-Kaisy A, Arcioni R, Smith T, Negro A, Lambru G, Bandikatla V, Carson 
E, Martelletti P. A six year retrospective review of occipital nerve stimulation practice–
controversies and challenges of an emerging technique for treating refractory headache 
syndromes. The Journal of Headache and Pain. 2013 Aug 6;14:67
Transcranial Magnetic Stimulation in Neuropsychiatry134
[33] Mueller O, Diener H-C, Dammann P, Rabe K, Hagel V, Sure U, Gaul C. Occipital nerve 
stimulation for intractable chronic cluster headache or migraine: A critical analysis 
of direct treatment costs and complications. Cephalalgia: An International Journal of 
Headache. 2013 Dec;33(16):1283-1291
[34] Wilbrink LA, Teernstra OPM, Haan J, van Zwet EW, Evers SMAA, Spincemaille GH, 
Veltink PH, Mulleners W, Brand R, Huygen FJPM, Jensen RH, Paemeleire K, Goadsby 
PJ, Visser-Vandewalle V, Ferrari MD. Occipital nerve stimulation in medically intracta-
ble, chronic cluster headache. The ICON study: Rationale and protocol of a randomised 
trial. Cephalalgia: An International Journal of Headache. 2013 Nov;33(15):1238-1247
[35] Brewer AC, Trentman TL, Ivancic MG, Vargas BB, Rebecca AM, Zimmerman RS, 
Rosenfeld DM, Dodick DW. Long-term outcome in occipital nerve stimulation patients 
with medically intractable primary headache disorders. Neuromodulation Journal of 
International Neuromodulation Society. 2013 Dec;16(6):557-562-564
[36] Narouze SN, Kapural L. Supraorbital nerve electric stimulation for the treatment of 
intractable chronic cluster headache: A case report. Headache. 2007 Aug;47(7):1100-1102
[37] Elahi F, Reddy C. Neuromodulation of the great auricular nerve for persistent post-
traumatic headache. Pain Physician. 2014 Aug;17(4):E531-E536
[38] Tepper SJ, Caparso A. Sphenopalatine ganglion (SPG): Stimulation mechanism, safety, 
and efficacy. Headache. 2017 Apr;57(Suppl 1):14-28
[39] Meng D-W, Zhang J-G, Zheng Z, Wang X, Luo F, Chronic Bilateral ZK. Sphenopalatine 
ganglion stimulation for intractable bilateral chronic cluster headache: A case report. 
Pain Physician. 2016;19(4):E637-E642
[40] Fontaine D, Vandersteen C, Magis D, Lanteri-Minet M. Neuromodulation in cluster 
headache. Advances and Technical Standards in Neurosurgery. 2015;42:3-21
[41] Narouze S. Neurostimulation at pterygopalatine fossa for cluster headaches and cere-
brovascular disorders. Current Pain and Headache Reports. 2014 Jul;18(7):432
[42] Jürgens TP, Schoenen J, Rostgaard J, Hillerup S, Láinez MJA, Assaf AT, May A, Jensen 
RH. Stimulation of the sphenopalatine ganglion in intractable cluster headache: Expert 
consensus on patient selection and standards of care. Cephalalgia: An International 
Journal of Headache. 2014 Nov;34(13):1100-1110
[43] Jürgens TP, Barloese M, May A, Láinez JM, Schoenen J, Gaul C, Goodman AM, Caparso 
A, Jensen RH. Long-term effectiveness of sphenopalatine ganglion stimulation for clus-
ter headache. Cephalalgia: An International Journal of Headache. 2017 Apr;37(5):423-434
[44] Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: 
What is the rationale? Cephalalgia: An International Journal of Headache. 2014 Apr;34(5): 
382-391
[45] Lambru G, Trimboli M, Palmisani S, Smith T, Al-Kaisy A. Safety and efficacy of cervical 
10 kHz spinal cord stimulation in chronic refractory primary headaches: A retrospective 
case series. The Journal of Headache and Pain. 2016 Dec;17(1):66
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
135
[46] Arcioni R, Palmisani S, Mercieri M, Vano V, Tigano S, Smith T, Fiore MRD, Al-Kaisy A, 
Martelletti P. Cervical 10 kHz spinal cord stimulation in the management of chronic, 
medically refractory migraine: A prospective, open-label, exploratory study. European 
Journal of Pain London England. 2016 Jan;20(1):70-78
[47] De Agostino R, Federspiel B, Cesnulis E, Sandor PS. High-cervical spinal cord stimulation 
for medically intractable chronic migraine. Neuromodulation Journal of International 
Neuromodulation Society. 2015 Jun;18(4):289-296 discussion 296
[48] Elahi F, Reddy C. High cervical epidural neurostimulation for post-traumatic headache 
management. Pain Physician. 2014 Aug;17(4):E537-E541
[49] Miller S, Akram H, Lagrata S, Hariz M, Zrinzo L, Matharu M. Ventral tegmental area 
deep brain stimulation in refractory short-lasting unilateral neuralgiform headache 
attacks. Brain: A Journal of Neurology. 2016 Oct;139(Pt 10):2631-2640
[50] Leone M, Proietti Cecchini A. Deep brain stimulation in headache. Cephalalgia: An 
International Journal of Headache. 2015 Dec 7
[51] Avecillas-Chasin JM, Alonso-Frech F, Parras O, Del Prado N, Barcia JA. Assessment of 
a method to determine deep brain stimulation targets using deterministic tractography 
in a navigation system. Neurosurgical Review. 2015 Oct;38(4):739-750; discussion 751
[52] Seijo F, Saiz A, Lozano B, Santamarta E, Alvarez-Vega M, Seijo E, Fernández de León R, 
Fernández-González F, Pascual J. Neuromodulation of the posterolateral hypothalamus 
for the treatment of chronic refractory cluster headache: Experience in five patients with 
a modified anatomical target. Cephalalgia: An International Journal of Headache. 2011 
Dec;31(16):1634-1641
[53] Farber SH, Hatef J, Han JL, Marky AH, Xie J, Huang K, Verla T, Lokhnygina Y, Collins TA, 
Lad SP. Implantable Neurostimulation for headache disorders: Effect on healthcare uti-
lization and expenditures. Neuromodulation Journal of International Neuromodulation 
Society. 2016 Apr;19(3):319-328
[54] Barolat G, Ketcik B, He J. Long-term outcome of spinal cord stimulation for chronic pain 
management. Neuromodulation Journal of International Neuromodulation Society. 
1998 Jan;1(1):19-29
[55] Leone M. Deep brain stimulation in headache. Lancet Neurology. 2006 Oct;5(10):873-877
[56] Schwalb JM, Hamani C. The history and future of deep brain stimulation. Neurother: 
Journal of the American Society for Experimental Neurotherapeutics. 2008 Jan;5(1):3-13
[57] Mazars G, Pull H. Neurosurgical treatment of headaches. Minerva Medica. 1976 Jun 
23;67(31):2020-2022
[58] Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. 
Chronic effects of implanted devices. Applied Neurophysiology. 1977-1978;40(2-4):223-234
[59] Wichmann T, Delong MR. Deep brain stimulation for neurologic and neuropsychiatric 
disorders. Neuron. 2006 Oct 5;52(1):197-204
Transcranial Magnetic Stimulation in Neuropsychiatry136
[60] Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital 
neuralgia. Neuromodulation Journal of International Neuromodulation Society. 1999 
Jul;2(3):217-221
[61] Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for 
treatment of chronic intractable cluster headaches: First reported series. Neurosurgery. 
2003 May;52(5):1095-1099-1101
[62] Dunteman E. Peripheral nerve stimulation for unremitting ophthalmic postherpetic 
neuralgia. Neuromodulation Journal of International Neuromodulation Society. 2002 
Jan;5(1):32-37
[63] Matharu MS, Bartsch T, Ward N, Frackowiak RSJ, Weiner R, Goadsby PJ. Central neu-
romodulation in chronic migraine patients with suboccipital stimulators: A PET study. 
Brain: A Journal of Neurology. 2004 Jan;127(Pt 1):220-230
[64] Wolter T, Kaube H, Mohadjer M. High cervical epidural neurostimulation for clus-
ter headache: Case report and review of the literature. Cephalalgia: An International 
Journal of Headache. 2008 Oct;28(10):1091-1094
[65] Barker AT, Shields K. Transcranial magnetic stimulation: Basic principles and clinical 
applications in migraine. Headache. 2017 Mar;57(3):517-524
[66] McComas AJ, Upton ARM. Transcranial magnetic stimulation in migraine: A new ther-
apy and new insights into pathogenesis. Critical Reviews in Biomedical Engineering. 
2016;44(5):319-326
[67] Kalita J, Bhoi SK, Misra UK. Effect of high rate rTMS on somatosensory evoked potential in 
migraine. Cephalalgia: An International Journal of Headache. 2017 Nov;37(13):1222-1230
[68] Conforto AB, Amaro E, Gonçalves AL, Mercante JP, Guendler VZ, Ferreira JR, Kirschner 
CC, Peres MF. Randomized, proof-of-principle clinical trial of active transcranial 
magnetic stimulation in chronic migraine. Cephalalgia: An International Journal of 
Headache. 2014 May;34(6):464-472
[69] Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ. Single-
pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: 
Evaluation of outcome data for the UK post market pilot program. The Journal of 
Headache and Pain. 2015;16:535
[70] Zardouz S, Shi L, Leung A. A feasible repetitive transcranial magnetic stimulation clini-
cal protocol in migraine prevention. SAGE Open Medical Case Report. 2016;4 20503 
13X16675257
[71] Lan L, Zhang X, Li X, Rong X, Peng Y. The efficacy of transcranial magnetic stimulation 
on migraine: A meta-analysis of randomized controlled trails. The Journal of Headache 
and Pain. 2017 Aug 22;18(1):86
[72] Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial 
magnetic stimulation and potential cortical and trigeminothalamic mechanisms in 
migraine. Brain: A Journal of Neurology. 2016 Jul;139(Pt 7):2002-2014
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
137
[73] Rapinesi C, Del Casale A, Scatena P, Kotzalidis GD, Di Pietro S, Ferri VR, Bersani FS, 
Brugnoli R, Raccah RN, Zangen A, Ferracuti S, Orzi F, Girardi P, Sette G. Add-on deep 
Transcranial magnetic stimulation (dTMS) for the treatment of chronic migraine: A pre-
liminary study. Neuroscience Letters. 2016 Jun 3;623:7-12
[74] Cosentino G, Fierro B, Vigneri S, Talamanca S, Paladino P, Baschi R, Indovino S, Maccora 
S, Valentino F, Fileccia E, Giglia G, Brighina F. Cyclical changes of cortical excitability 
and metaplasticity in migraine: Evidence from a repetitive transcranial magnetic stimu-
lation study. Pain. 2014 Jun;155(6):1070-1078
[75] Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in 
migraine prophylaxis: A randomized, placebo-controlled study. Journal of Neurology. 
2013 Nov;260(11):2793-2801
[76] Shehata HS, Esmail EH, Abdelalim A, El-Jaafary S, Elmazny A, Sabbah A, Shalaby 
NM. Repetitive transcranial magnetic stimulation versus botulinum toxin injection 
in chronic migraine prophylaxis: A pilot randomized trial. Journal of Pain Research. 
2016;9:771-777
[77] Hodaj H, Alibeu J-P, Payen J-F, Lefaucheur J-P. Treatment of chronic facial pain includ-
ing cluster headache by repetitive Transcranial magnetic stimulation of the motor cortex 
with maintenance sessions: A naturalistic study. Brain Stimulation. 2015 Aug;8(4):801-807
[78] Durmaz O, Ateş MA, Şenol MG. Repetitive Transcranial magnetic stimulation (rTMS)-
induced trigeminal autonomic Cephalalgia. Noro Psikiyatri Arsivi. 2015 Sep;52(3):309-311
[79] Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient 
with intractable epilepsy. Cephalalgia: An International Journal of Headache. 2002 
Jul;22(6):482-484
[80] Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, 
Rubenstein Engel E, Tepper SJ. ACT1 study group. Non-invasive vagus nerve stimula-
tion for the acute treatment of cluster headache: Findings from the randomized, double-
blind, sham-controlled ACT1 study. Headache. 2016 Sep;56(8):1317-1332
[81] Gaul C, Diener H-C, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube 
A, PREVA Study Group. Non-invasive vagus nerve stimulation for prevention and 
acute treatment of chronic cluster headache (PREVA): A randomised controlled study. 
Cephalalgia: An International Journal of Headache. 2016 May;36(6):534-546
[82] Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine with 
transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): 
A randomized, monocentric clinical trial. The Journal of Headache and Pain. 2015;16:543
[83] Eren O, Straube A, Schöberl F, Schankin C. Hemicrania continua: Beneficial effect of 
non-invasive Vagus nerve stimulation in a patient with a contraindication for indometh-
acin. Headache. 2017 Feb;57(2):298-301
[84] Akbas M, Gunduz E, Sanli S, Yegin A. Sphenopalatine ganglion pulsed radiofrequency 
treatment in patients suffering from chronic face and head pain. Brazilian Journal of 
Anesthesiology Elsevier. 2016 Feb;66(1):50-54
Transcranial Magnetic Stimulation in Neuropsychiatry138
[85] Barloese MCJ, Jürgens TP, May A, Lainez JM, Schoenen J, Gaul C, Goodman AM, 
Caparso A, Jensen RH. Cluster headache attack remission with sphenopalatine ganglion 
stimulation: Experiences in chronic cluster headache patients through 24 months. The 
Journal of Headache and Pain. 2016 Dec;17(1):67
[86] Assaf AT, Hillerup S, Rostgaard J, Puche M, Blessmann M, Kohlmeier C, Pohlenz P, Klatt 
JC, Heiland M, Caparso A, Papay F. Technical and surgical aspects of the sphenopalatine 
ganglion (SPG) microstimulator insertion procedure. International Journal of Oral and 
Maxillofacial Surgery. 2016 Feb;45(2):245-254
[87] Schoenen J, Jensen RH, Lantéri-Minet M, Láinez MJA, Gaul C, Goodman AM, Caparso 
A, May A. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache 
treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia: An 
International Journal of Headache. 2013 Jul;33(10):816-830
[88] Magis D, Allena M, Bolla M, De Pasqua V, Remacle J-M, Schoenen J. Occipital nerve 
stimulation for drug-resistant chronic cluster headache: A prospective pilot study. 
Lancet Neurology. 2007 Apr;6(4):314-321
[89] Shaw AB, Sharma M, Shaikhouni A, Marlin ES, Ikeda DS, McGregor JM, Deogaonkar 
M. Neuromodulation as a last resort option in the treatment of chronic daily head-
aches in patients with idiopathic intracranial hypertension. Neurology India. 2015 
Oct;63(5):707-711
[90] Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic migraine: 
A single-center experience, review of literature, and surgical considerations. Neurosurgical 
Focus. 2013 Sep;35(3):E9
[91] Kinfe TM, Pintea B, Roeske S, Güresir Á, Güresir E, Vatter H. Percutaneous nerve field 
stimulation (PENS) of the occipital region as a possible predictor for occipital nerve 
stimulation (ONS) responsiveness in refractory headache disorders? A feasibility study. 
Cephalalgia: An International Journal of Headache. 2016 Jul;36(8):779-789
[92] Son B-C, Yang S-H, Hong J-T, Lee S-W. Occipital nerve stimulation for medically refrac-
tory hypnic headache. Neuromodulation Journal of International Neuromodulation 
Society. 2012 Jul;15(4):381-386
[93] Lambru G, Shanahan P, Watkins L, Matharu MS. Occipital nerve stimulation in the treat-
ment of medically intractable SUNCT and SUNA. Pain Physician. 2014 Feb;17(1):29-41
[94] Miller S, Watkins L, Matharu M. Long-term follow up of intractable chronic short last-
ing unilateral neuralgiform headache disorders treated with occipital nerve stimulation. 
Cephalalgia: An International Journal of Headache. 2017 Jan 1 333102417721716
[95] Tavanaiepour D, Levy RM. Peripheral neuromodulation for treatment of chronic mig-
raine headache. Neurosurgery Clinics of North America. 2014 Jan;25(1):11-14
[96] Sharan A, Huh B, Narouze S, Trentman T, Mogilner A, Vaisman J, Ordia J, Deer T, 
Venkatesan L, Slavin K. Analysis of adverse events in the management of chronic migraine 
by peripheral nerve stimulation. Neuromodulation Journal of International Neuro-
modulation Society. 2015 Jun;18(4):305-312 discussion 312
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
139
[97] Zimmerman RS, Rosenfeld DM, Freeman JA, Rebecca AM, Trentman TL. Revision of 
occipital nerve stimulator leads: Technical note of two techniques. Neuromodulation 
Journal of International Neuromodulation Society. 2012 Jul;15(4):387-391
[98] Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. 
Lancet Neurology. 2012 Aug;11(8):708-719
[99] Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM 
Investigators. Occipital nerve stimulation for the treatment of intractable chronic 
migraine headache: ONSTIM feasibility study. Cephalalgia: An International Journal 
of Headache. 2011 Feb;31(3):271-285
[100] Rogers LL, Swidan S. Stimulation of the occipital nerve for the treatment of migraine: 
Current state and future prospects. Acta Neurochirurgica. Supplement. 2007;97(Pt 1): 
121-128
[101] Abhinav K, Park ND, Prakash SK, Love-Jones S, Patel NK. Novel use of narrow paddle 
electrodes for occipital nerve stimulation--technical note. Neuromodulation Journal of 
International Neuromodulation Society. 2013 Dec;16(6):607-609
[102] Wolter T, Kiemen A, Kaube H. High cervical spinal cord stimulation for chronic cluster 
headache. Cephalalgia: An International Journal of Headache. 2011 Aug;31(11):1170-1180
[103] Fontaine D, Lanteri-Minet M, Ouchchane L, Lazorthes Y, Mertens P, Blond S, Geraud 
G, Fabre N, Navez M, Lucas C, Dubois F, Sol JC, Paquis P, Lemaire JJ. Anatomical loca-
tion of effective deep brain stimulation electrodes in chronic cluster headache. Brain: A 
Journal of Neurology. 2010 Apr;133(Pt 4):1214-1223
[104] Matharu MS, Zrinzo L. Deep brain stimulation in cluster headache: Hypothalamus or 
midbrain tegmentum? Current Pain and Headache Reports. 2010 Apr;14(2):151-159
[105] Headache Classification Committee of the International Headache Society (IHS). The 
international classification of headache disorders, 3rd edition (beta version). Cephalalgia: 
An International Journal of Headache. 2013 Jul;33(9):629-808
[106] Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster 
headache: A meta-analysis of population-based studies. Cephalalgia: An International 
Journal of Headache. 2008 Jun;28(6):614-618
[107] Nesbitt AD, Marin JCA, Tompkins E, Ruttledge MH, Goadsby PJ. Initial use of a novel 
noninvasive vagus nerve stimulator for cluster headache treatment. Neurology. 2015 
Mar 24;84(12):1249-1253
[108] Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repeti-
tive sphenopalatine ganglion block: A case report. Headache. 2016 Mar;56(3):573-579
[109] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon 
JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, 
Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, 
Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez M-G, Baxter A, Bell ML, 
Transcranial Magnetic Stimulation in Neuropsychiatry140
Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, 
Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous 
S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, 
Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch 
M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, 
Carmona L, Cella C, Charlson F, Chen H, Cheng AT-A, Chou D, Chugh SS, Coffeng 
LE, Colan SD, Colquhoun S, Colson KE, Condon J, et al. Years lived with disability 
(YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis 
for the Global Burden of Disease Study 2010. Lancet London England. 2012 Dec 15; 
380(9859):2163-96.
[110] Irimia P, Palma J-A, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a 
headache clinic population. BMC Neurology. 2011 Aug;11(1):94
[111] Magis D. Neuromodulation in migraine: State of the art and perspectives. Expert 
Review of Medical Devices. 2015 May;12(3):329-339
[112] Seifert TD, Evans RW. Posttraumatic headache: A review. Current Pain and Headache 
Reports. 2010 Aug;14(4):292-298
Chronic Headache and Neuromodulation
http://dx.doi.org/10.5772/intechopen.72150
141

